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In this issue ofCancer Cell, Murphy et al. describe amouse model designed to examine the biological effects
of different levels of deregulated c-myc expression. They provide evidence that distinct threshold levels of
Myc are required for increased proliferation and for apoptosis in different tissues.The myc gene family encodes essential
transcription factors whose expression is
altered in awide variety of humancancers.
In nearly all tissues, normal proliferating
cells express low levels of myc RNA and
protein in response to a broad range of
mitogenic stimuli. The vast majority of
cancer-associated genetic changes in
myc are associated with noncoding regu-
latory regions rather than protein-coding
sequences. This has led to the argument
that it is the deregulation of myc expres-
sion, as opposed to a change in Myc
protein functionality, that is important in
tumorigenesis. Deregulation can take sev-
eral forms: for example, Myc may remain
at or near normal levels but be resistant
to modulation in response to appropriate
signals. Alternatively, Myc may be highly
overexpressed as well as resistant to reg-
ulation. In other words, in tumors, Myc is
‘‘locked on’’ at either high or low levels.
In termsofMyc’s ability to promote tumor-
igenesis, we would like to know whether it
is the absolute level of expression or the
inability to control expression, or both,
that is most important.
There is ample evidence that maintain-
ing precise levels of Myc is an important
matter in cells. Myc abundance is regu-
lated at transcriptional, posttranscrip-
tional, and posttranslational levels in
response to numerous mitogenic signal
transduction pathways. Given the high
rate of synthesis and turnover of myc
mRNA and protein, it can be argued that
the concentration of Myc at any moment
serves as a sensor and integrator of the
signaling environment, converting exter-
nal and internal input into gene expression
programs (for recent review, see Eilers
and Eisenman, 2008). Yet we do not
know specifically how different levels of
Myc are ‘‘interpreted’’ by cells. Studies of
myc loss-of-function alleles have indi-
cated that at least someMyc is necessaryfor cellular function. Knockout of myc
family genes in rodent fibroblasts and
numerous other cell types rapidly inhibits
or attenuates proliferation. However, in rat
fibroblasts, heterozygosity at the c-myc
locus causing a 50% reduction in c-Myc
levels results in only a modest decrease
in cell proliferation, while transformation
by activated Ras or Raf is severely com-
promised (Bazarov et al., 2001). In con-
trast, Myc overexpression results in multi-
ple changes in cell behavior. An important
aspect of the cellular response to overex-
pressed Myc is the activation of apoptotic
and senescence pathways that function
as tumor-suppressive barriers to limit
Myc’s hyperproliferative signal (Grandori
et al., 2003; Green and Evan, 2002). None-
theless, such barriers tend to collapse
during tumor progression. Because myc
expression can vary widely, an important
question is whether there exist distinct
thresholds of response to increasing
levels of Myc.
In this issue of Cancer Cell, Murphy and
colleagues (Murphy et al., 2008) describe
a mouse model in which they analyze the
effects of relatively low levels of deregu-
lated c-Myc. The authors employed an
inducible MycER fusion protein constitu-
tively expressed under the control of the
Rosa26 locus (R26lsl-MER mice). In this
system, MycER is turned on by expres-
sion of Cre recombinase, resulting in
expression of an inactive form of Myc
protein. MycER is then acutely activated
whenmice are administered 4-hydroxyta-
moxifen ligand. The amounts of Myc
expressed from the Rosa26 locus were
dependent on gene dose: mice express-
ing two deregulated alleles of c-myc
(R26MER/MER) expressed approximately
twice as much c-myc RNA in all tissues
examined asmice containing one deregu-
lated allele (R26MER/WT). Note that be-
cause in most cases it is c-myc RNACancer Cell 14that is being quantified, an implicit as-
sumption is that differences in mRNA
levels are reflected by roughly equivalent
differences in Myc protein levels. In the
pancreas, R26MER/WT and R26MER/MER
mice expressed a 1.5- and 2-fold in-
crease, respectively, over physiologic
levels of Myc. In mice harboring one
deregulated allele (R26MER/WT), there
was no measurable increase in cell prolif-
eration in the pancreas, indicating that
this amount of Myc did not demonstrably
alter cell physiology. However, in mice
with two deregulated c-myc alleles
(R26MER/MER), a robust increase in cell
proliferation was observed in the pan-
creas. Therefore, an increase of between
1.5- and 2-fold over endogenous Myc
appears to be the amount required
in vivo to stimulate pancreatic cell prolifer-
ation. The absolute levels of deregulated
c-myc expressed from the Rosa26 locus
varied considerably between tissues.
However, in most tissues, two deregu-
lated c-myc alleles (R26MER/MER) were
required to increase cell proliferation.
Furthermore, the augmented proliferation
seen in the lungs of R26MER/MER mice
(which expressed 5-fold increased
Myc) was sufficient to induce hyperplasia,
and when these mice were crossed with
amouse strain harboring a conditional ac-
tivated Rasmutation (RasG12D), frank lung
tumors were generated.
Apoptosis, through activation of the
ARF-Mdm2-p53 pathway, is a common
outcomeofMycderegulation andacritical
barrier to Myc-dependent oncogenesis. A
particularly intriguing finding by Murphy
et al. is that apoptosis was not activated
in most tissues of the R26MER/MER mice,
indicating that modestly increasing Myc
abundance and stimulating proliferation
does not activate this important mecha-
nism of tumor avoidance. Consistent
with this finding, the tumor suppressor, December 9, 2008 ª2008 Elsevier Inc. 425
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of proliferation and hyperplasia. However,
apoptosis was readily detected when
these same mice were given doxorubicin.
This indicates that the mice were sensi-
tized to apoptotic stimuli by a 2-fold in-
crease in Myc and suggests that the
Myc-induced apoptotic program, while
not overtly activated, was in some way
‘‘primed’’ and required additional signals
to become manifest. Furthermore, when
the authors constitutively expressed large
amountsofMyc (15-fold over endogenous
levels) in the pancreas, proliferation, ARF,
and apoptosis were activated. Therefore,
somewhere between a 2- and 15-fold
increase in the levels of deregulated Myc
is required to provoke an apoptotic re-
sponse. This is consistent with the finding
that in R26MER/MER mice, the colonic epi-
thelium, which expresses considerably
higher Myc levels than other tissues,
shows ARF activation and apoptosis.
This study raises important questions
concerning the mechanisms underlying
the differential cellular response to rela-
tively small variations in Myc levels. Myc,
primarily in association with its obligate
dimerization partner Max, has been
reported to bind on the order of 15% of
genomic loci and to cause widespread
changes in gene expression (Fernandez
et al., 2003; Orian et al., 2003). What
targets of Myc are turned on when Myc
expression is approximately twice its
physiologic amount and proliferation is in-
creased? One possibility is that more Myc
simply amplifies the same transcriptional
response induced by lower levels of
Myc. Another is that increased levels of
Myc result in binding to new sites and an
expansion of the transcriptional re-
sponse—an idea that has received some
support from genomic binding studies
(Fernandez et al., 2003; Zeller et al.,
2006) (Figure 1). Increasing levels of Myc
may also trip other cellular switches, for
example by inducing or inhibiting clusters
of microRNAs (Lotterman et al., 2008), in-
teracting with other transcription factors,
Figure 1. Differential Effects on Target Gene Expression by Endogenous and Deregulated
Myc
Twomodels for how different levels ofMyc influence gene expression programs.Myc protein expressed at
physiologic levels (depicted as blue ovals) from the endogenous myc locus occupies promoters of target
genes (green boxes) and activates gene expression. Arrowhead size corresponds to relative level of ex-
pression. Some potential Myc target genes (red boxes) are not bound or activated by endogenous or
low levels of Myc (e.g., due to low-affinity Myc binding sites). Following deregulation, low or high levels
of Myc protein (shown as blue ovals with red borders) may either bind and amplify expression of the
same Myc target genes as endogenous Myc (model 1) or bind and increase expression of additional
Myc targets (model 2). At low Myc levels, the new targets may become ‘‘sensitized’’ in that other signaling
pathways can cooperate with Myc to activate gene expression, a requirement that may not be necessary
at high levels of Myc. Myc target genes in the apoptotic pathway may be examples of this effect.426 Cancer Cell 14, December 9, 2008 ª2008 Elsevier Inc.or stimulating DNA replication (Domi-
nguez-Sola et al., 2007).
The work of Murphy et al. may have
disappointing implications for cancer
therapies based on reducing Myc protein
levels. Studies using the kinase inhibitor
imatinib indicate that even partial inhibi-
tion of oncogene function may achieve
remission of some tumors. However,
while antisense or drug-based inhibition
of Myc will suppress the high Myc levels
found during progression of many tu-
mors, the residual levels of Myc may be
sufficient to drive proliferation of cells
that now have an attenuated apoptotic
response. From the therapeutic point of
view, it may be considerably more im-
portant to elucidate, and then find ways
to inhibit, the specific transcriptional
targets of Myc that are most critical for
tumorigenesis.
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